Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Cyclophosphamide

Review the clinical trials studying cyclophosphamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 420

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
Status: Active
Location: 2 locations
GD2CART for the Treatment of H3K27M Mutated Diffuse Intrinsic Pontine Glioma or Spinal Diffuse Midline Glioma
Status: Active
Location: 2 locations
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Status: Active
Location: 2 locations
Genetically Engineered Cells (Autologous Anti-HER2 CAR-CD28 T Cells) in Combination with Immune Checkpoint Inhibitors for the Treatment of Advanced Sarcoma
Status: Active
Location: 2 locations
Genetically Engineered Cells (C7R-GD2.CAR T Cells) for the Treatment of Patients with GD2-Expressing High Grade Glioma or Diffuse Intrinsic Pontine Glioma, The GAIL-B Trial
Status: Active
Location: 2 locations
Cytokine-Induced Memory-Like Natural Killer Cells and Interleukin-2 with Venetoclax as Consolidation Therapy for the Treatment of Acute Myeloid Leukemia
Status: Active
Location: 2 locations
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Status: Active
Location: 2 locations
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Status: Active
Location: 2 locations
Genetically Engineered Immune Cells (TriCAR-ALL T-Cells) for the Treatment of Recurrent or Refractory CD19, CD20, and/or CD22 Positive B-Cell Acute Lymphoblastic Leukemia
Status: Active
Location: 2 locations
Cytokine-Induced Memory-Like Natural Killer Cell Therapy for the Treatment of Recurrent Ovarian Cancer
Status: Active
Location: 2 locations
CD4CAR T Cell Therapy for the Treatment of Patients with Relapsed or Refractory CD4 Positive CMML
Status: Active
Location: 2 locations
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Status: Active
Location: 2 locations
T Cells (EAGD T-Cells) after Stem Cell Transplantation and Post-transplant Cyclophosphamide for the Treatment of Blood Cancers
Status: Active
Location: 2 locations
Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) for the Treatment of Children and Young Adults with Relapse or Refractory Neuroblastoma, Soft Tissue Sarcoma, Osteosarcoma, Ewing Sarcoma, and Wilms Tumor
Status: Active
Location: 2 locations
Modified Immune Cells (GD2 Specific Chimeric Antigen Receptor and IL-15 Expressing Autologous Natural Killer T-Cells) with or without Etanercept in Treating Children with Relapsed or Refractory Neuroblastoma
Status: Active
Location: 2 locations
Autologous CD22 Chimeric Antigen Receptor (CAR) T cells following Commercial CD19 CAR T cells for the Treatment of Children and Young Adults with Recurrent or Refractory B Cell Acute Lymphoblastic Leukemia
Status: Active
Location: 2 locations
A Vaccine (VSV-hIFNβ-NIS) with or without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Status: Active
Location: 2 locations
Cytokine Induced Memory-Like Natural Killer Cells in Combination with Aldesleukin for the Treatment of Locally Advanced or Metastatic Renal Cell Cancer or Urothelial Cancer
Status: Active
Location: 2 locations
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia, INFLUENCE Trial
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes, and Aldesleukin in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Cyclophosphamide and Sirolimus and in Treating Patients with Metastatic, Radioiodine-Refractory Thyroid Cancer
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Cyclophosphamide with Pembrolizumab in Treating Checkpoint Inhibitor Refractory Stage III or IV Melanoma
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Autologous Hematopoietic Stem Cell Transplant for the Treatment of Children and Young Adults with Systemic Sclerosis or Systemic Lupus Erythematosus
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
A Study of Whether Ide-Cel (bb2121) Can Be Made From People with Relapsed or Refractory Multiple Myeloma who have had a Hematopoietic Cell Transplant
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Cell Therapy (Tumor Infiltrating Lymphocytes) and Aldesleukin in Treating Patients with Locally Advanced, Recurrent, Refractory, or Metastatic Biliary Tract Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania